

Company Location

4645 E. Cotton Center Blvd.
Building 2, Suite 171
Phoenix, AZ 85040

Contact Numbers

Tel: (480) 505-9466
Fax: (480) 505-9476

Contact 1

Keri Voss
Title: Dir. Business Oper.
kvoss@histatek.com
Extension x222

Contact 2

John Lipani
Title: CEO/President
jlipani@histatek.com
Extension x227

Company Overview

Histatek, Inc. is a 6 year old biopharmaceutical company focused on the development of anti-inflammatory small peptides for the treatment of rheumatoid arthritis, asthma and other inflammatory conditions. Histatek's seasoned management team has over 130 years of industry based drug development experience.

Expertise

Number of Employees	5
PhD	2
MS	2
Other Degreed	1





Awards

1. Fellow American College of Rheumatology

Specific Scientists

1. Garrett Lindermann, Ph.D.
2. Emil Chi, Ph.D

Core Competencies



Business Outlook

Mission Statement

Histatek will utilize its proprietary systems biology to conduct early stage drug development through Phase II clinical trials, accelerating compounds to FDA approval faster, better and cheaper.

Commercialization Strategy The Company goal is to develop products through Phase II and partner with a large pharmaceutical to complete registration trials and bring the product to market.

Problems The major problem of early stage drug development is the demonstration of an acceptable drug safety profile. Histatek has carefully evaluated its lead products in multiple species and a full range of dose exposures to establish a very satisfactory therapeutic index.


Products and Services

Patents *Which Patents:* Histatek has issued patents covering the basic mechanisms of action of the compounds as well as the use of the appropriate receptors involved.

Drug Development *Which Drugs:* HK-X: a small peptide with demonstrated activity in models of inflammatory arthritis, asthma and inflammatory skin disorders.

Clinical Studies *Which Studies:* the Histatek development team collectively has conducted over 500 clinical trials, either as primary investigators or as Industry based clinical monitors. The experience ranges from phase I to Phase IV post marketing trials.

Needs and Interests



Synergistic or Strategic Opportunities

What kinds of partnerships are of interest?

Histatek is interested in outsourcing much of its discovery efforts to concentrate on the development of the established pipeline. Collaborative work in genomics/proteomic; mechanism of action studies; and development of novel delivery systems will be sought.